Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs)

learn more

UNADDRESSED PATIENT NEEDS

IMIDs are a significant detriment to quality of life for millions of patients

>10M

In the US affected by IMIDs

>$100B

Annual US economic burden from IMIDs

4 of 5

Ulcerative Colitis patients fail to achieve remission

half

Systemic Lupus Erythematosus patients require >1YR for correct diagnosis

5 YRS

Reduced life expectancy for RA patients

WHAT MAKES IMIDOMICS DIFFERENT

Our Clinical Discovery Engine is built on proprietary IMIDomics patient data collected by the IMID Consortium specifically for drug target discovery and patient stratification purposes

learn more
Image
Our access to patients allows us to go back for additional samples and recruiting for clinical trials.
learn more

Data-Driven

The Spanish IMID Investigator Consortium: a living resource for IMIDomics

>17

years of data and sample collection

>130

recruiting centers

>300

investigators

Currently targeting eight diseases:

  • Systemic Lupus Erythematosus
  • Ulcerative Colitis
  • Crohn’s Disease
  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Sjögren’s Syndrome
Map with numbers
16
1
1
2
11
4
3
5
12
5
6
34
6
25
7
To follow the patients’ journey -
we have the ability to recontact patients
IMID diseases evolve over time, so we collect and analyze cross-sectional and longitudinal data across Spain and Paraguay.
>17,000

IMID patients and control subjects

>10,000

Clinical variables collected across the eight IMIDs

>2M

Clinical and epidemiological data points

>1M

Biological specimens (blood and relevant tissues)

UNIQUE DRUG TARGETS

Integration of our multi-dimensional patient data and use of advanced computational analysis enable us to make precision-targeted discoveries

LEARN MORE
LEARN MORE

LEVERAGING DRUG DEVELOPMENT EXPERTISE AT EVERY LEVEL

Precision discovery feeds full-scale development of our pipeline

Illustration
Icon
Six targets have entered our pipeline, initially focusing on SLE and IBDs
Icon
Patient stratification strategies being developed for each target in different IMIDs
Icon
Leveraging industry partnerships to accelerate our pipeline
SEE OUR PIPELINE

COLLABORATING WITH GLOBAL EXPERTS

Key partners and advisors at every stage

Photo
“IMIDomics have assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking and analytics.”

Luisa Salter-Cid, Ph.D.,

Chief Scientific Officer at Pioneering Medicines

Photo
“IMIDomics is uniquely positioned to generate new and important insights that aid in the development of therapeutics to treat IMIDs.”

Michael Pucker,

Chairman and CEO of
DNS Capital

Photo
“To access similar data and capabilities elsewhere would require multiple collaborations with individual clinics, universities, analysis labs, and expert data analytical groups.”

Peter Schafer, Ph.D.,

Executive Director, Translational Medicine at Bristol-Myers Squibb

OUR INVESTORS

Backed by industry leaders

Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases
Fred Craves Ph.D.
Fred Craves Ph.D.
Chairman and Chief Executive Officer

Dr. Craves is the Executive Chairman and CEO of IMIDomics and has been involved in the company since it was founded. He was formerly the Founder of Bay City Capital life science investment firm.

As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry, including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture-backed biotech company at that time. Today, Dr. Craves brings decades of experience to the leadership of IMIDomics.


Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of IMIDomics, Inc., Madrigal Pharmaceuticals, Synchronicity Pharma and the Gladstone Foundation. Previous investments and board participation, in addition to Reliant Pharmaceuticals, include Medarex, Inc., Incyte Biosciences, Dermira Pharmaceuticals, Twist Bioscience and Ion Torrent. He earned a BS in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco.

Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases
Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases